| 综述 |
|
|
|
|
| 自组装多肽在新型药物制剂研发领域中的应用 |
| 邵明香1,2, 龚珉1, 汤立达1,2 |
1. 天津药物研究院 释药技术与药代动力学国家重点实验室 天津市新药设计与发现重点实验室 天津 300193;
2. 天津医科大学 天津 300080 |
|
| Utility of the Self-assembling Peptides as Novel Drug Formulations |
| SHAO Ming-xiang1,2, GONG Min1, TANG Li-da1,2 |
1. State Key Laboratory of Drug Delivery Technology and Pharmaceutics, Tianjin Key Laboratory of Molecular Design and Drug Discovery, Tianjin Institute of Pharmaceutical Research, Tianjin 300193, China;
2. Pharmacology, Tianjin Medical University, Tianjin 300080, China |
[1] Lipinski C A. Drug-like properties and the causes of poor solubility and poor permeability. J Pharmacol Toxicol Methods, 2000,44:235-249.
[2] Stella V J,Nti-Addae K W. Prodrug strategies to overcome poor water solubility. Adv Drug Deliv Rev, 2007,59:677-694.
[3] Allen T M,Cullis P R. Drug delivery systems: entering the mainstream. Science, 2004,303:1818-1822.
[4] Tang Y,Heaysman C L,Willis S,et al. Physical hydrogels with self-assembled nanostructures as drug delivery systems. Expert Opin Drug Deliv, 2011,8:1141-1159.
[5] Reches M,Gazit E. Molecular self-assembly of peptide nanostructures: mechanism of association and potential uses. Current Nanoscience, 2006,2:105-111.
[6] Gummel J,Sztucki M,Narayanan T,et al. Concentration dependent pathways in spontaneous self-assembly of unilamellar vesicles. Soft Matter, 2011,7:5731-5738.
[7] Fu I W,Markegard C B,Chu B K,et al. The role of electrostatics and temperature on morphological transitions of hydrogel nanostructures self-assembled by peptide amphiphiles via molecular dynamics simulations. Adv Healthc Mater, 2013,doi: 10.1002/adhm.201200400.
[8] Tang J,Yao J,Shi J,et al. Synthesis, characterization, drug-loading capacity and safety of novel pH-independent amphiphilic amino acid copolymer micelles. Pharmazie, 2012,67:756-764.
[9] 许小丁,陈昌盛,陈荆晓,等. 多肽分子自组装. 中国科学, 2011,41(2):221-238. Xu X D, Cheng C S, Chen J X, et al. Molecular self-assembly of peptide. Scientia Sinica Chimica, 2011,41(2):221-238.
[10] Cui H,Webber M J,Stupp S I. Self-assembly of peptide amphiphiles: from molecules to nanostructures to biomaterials. Biopolymers, 2010,94:1-18.
[11] Hartgerink J D,Beniash E,Stupp S I. Peptide-amphiphile nanofibers: a versatile scaffold for the preparation of self-assembling materials. Proc Natl Acad Sci U S A, 2002,99:5133-5138.
[12] Velichko Y S,Stupp S I, Cruz M O. Molecular simulation study of peptide amphiphile self-assembly. J Phys Chem B, 2008,112:2326-2334.
[13] Cui H,Muraoka T,Cheetham A G,et al. Self-assembly of giant peptide nanobelts. Nano Lett, 2009,9:945-951.
[14] Webber M J,Kessler J A,Stupp S I. Emerging peptide nanomedicine to regenerate tissues and organs. J Intern Med, 2010,267:71-88.
[15] Sasso L,Vedarethinam I,Emneus J,et al. Self-assembled diphenylalanine nanowires for cellular studies and sensor applications. J Nanosci Nanotechnol, 2012,12:3077-3083.
[16] Jaime C L,Bake S W. Self-assembled peptide nanostructures for biomedical applications: advantages and challenges. Biomaterials Science and Engineering, 2011,25:115-138.
[17] Tarek M,Maigret B,Chipot C. Molecular dynamics investigation of an oriented cyclic peptide nanotube in DMPC bilayers. Biophys J, 2003,85:2287-2298.
[18] Yu T,Lee O S,Schatz G C. Steered molecular dynamics studies of the potential of mean force for peptide amphiphile self-assembly into cylindrical nanofibers. J Phys Chem A, 2013,DOI: 10.1021/jp401508w.
[19] Jana N R. Shape effect in nanoparticle self-assembly. Angew Chem Int Ed Engl, 2004,43:1536-1540.
[20] Kurzawa L,Pellerano M,Morris M C. PEP and CADY-mediated delivery of fluorescent peptides and proteins into living cells. Biochim Biophys Acta, 2010,1798:2274-2285.
[21] Eum W S,Kim D W,Hwang I K,et al. In vivo protein transduction: biologically active intact pep-1-superoxide dismutase fusion protein efficiently protects against ischemic insult. Free Radic Biol Med, 2004,37:1656-1669.
[22] Morris M C,Gros E,Aldrian-Herrada G,et al. A non-covalent peptide-based carrier for in vivo delivery of DNA mimics. Nucleic Acids Res, 2007,35:e49.
[23] Rittner K,Benavente A,Bompard-Sorlet A,et al. New basic membrane-destabilizing peptides for plasmid-based gene delivery in vitro and in vivo. Mol Ther, 2002,5:104-114.
[24] Zhang X X,Eden H S,Chen X. Peptides in cancer nanomedicine: drug carriers, targeting ligands and protease substrates. J Control Release, 2012,159:2-13.
[25] Konate K,Crombez L,Deshayes S,et al. Insight into the cellular uptake mechanism of a secondary amphipathic cell-penetrating peptide for siRNA delivery. Biochemistry, 2010,49:3393-3402.
[26] Crombez L,Divita G. A non-covalent peptide-based strategy for siRNA delivery. Methods Mol Biol, 2011,683:349-360.
[27] Deshayes S,Konate K,Rydstrom A,et al. Self-assembling peptide-based nanoparticles for siRNA delivery in primary cell lines. Small, 2012,8:2184-2188.
[28] Rydstrom A,Deshayes S,Konate K,et al. Direct translocation as major cellular uptake for CADY self-assembling peptide-based nanoparticles. PLoS One, 2011,6:e25924.
[29] Deshayes S,Konate K,Aldrian G,et al. Structural polymorphism of non-covalent peptide-based delivery systems: highway to cellular uptake. Biochim Biophys Acta, 2010,1798:2304-2314.
[30] Crowet J M,Lins L,Deshayes S,et al. Modeling of non-covalent complexes of the cell-penetrating peptide CADY and its siRNA cargo. Biochim Biophys Acta, 2013,1828:499-509.
[31] Cihlar T,Ray A S. Nucleoside and nucleotide HIV reverse transcriptase inhibitors: 25 years after zidovudine. Antiviral Res, 2010,85:39-58.
[32] Agopian A,Gros E,Aldrian-Herrada G,et al. A new generation of peptide-based inhibitors targeting HIV-1 reverse transcriptase conformational flexibility. J Biol Chem, 2009,284:254-264.
[33] Morris M C,Depollier J,Mery J,et al. A peptide carrier for the delivery of biologically active proteins into mammalian cells. Nat Biotechnol, 2001,19:1173-1176.
[34] Yao H J,Ju R J,Wang X X,et al. The antitumor efficacy of functional paclitaxel nanomicelles in treating resistant breast cancers by oral delivery. Biomaterials, 2011,32:3285-3302.
[35] Utreja P,Jain S,Tiwary A K. Evaluation of biosafety and intracellular uptake of Cremophor EL free paclitaxel elastic liposomal formulation. Drug Deliv, 2012,19:11-20.
[36] O'Connor T L,Kossoff E. Delayed seizure associated with paclitaxel-cremophorel in a patient with early-stage breast cancer. Pharmacotherapy, 2009,29:993-996.
[37] Rivkin I,Cohen K,Koffler J,et al. Paclitaxel-clusters coated with hyaluronan as selective tumor-targeted nanovectors. Biomaterials, 2010,31:7106-7114.
[38] Li S,Byrne B,Welsh J,et al. Self-assembled poly(butadiene)-b-poly(ethylene oxide) polymersomes as paclitaxel carriers. Biotechnol Prog, 2007,23:278-285.
[39] Van S,Das S K,Wang X,et al. Synthesis, characterization, and biological evaluation of poly(L-gamma-glutamyl-glutamine)-paclitaxel nanoconjugate. Int J Nanomedicine, 2010,5:825-837.
[40] Yokoi H,Kinoshita T,Zhang S. Dynamic reassembly of peptide RADA16 nanofiber scaffold. Proc Natl Acad Sci U S A, 2005,102:8414-8419.
[41] Liu J,Zhang L,Yang Z,et al. Controlled release of paclitaxel from a self-assembling peptide hydrogel formed in situ and antitumor study in vitro. Int J Nanomedicine, 2011,6:2143-2153.
[42] Li Y,Xu W,Tang L,et al. A novel GLP-1 analog exhibits potent utility in the treatment of type 2 diabetes with an extended half-life and efficient glucose clearance in vivo. Peptides, 2011,32:1408-1414.
[43] Zheng X,Li Y,Li X,et al. Peptide complex containing GLP-1 exhibited long-acting properties in the treatment of type 2 diabetes. Diabetes Res Clin Pract, 2011,93:410-420.
[44] Ruttimann E B,Arnold M,Geary N,et al. GLP-1 antagonism with exendin (9-39) fails to increase spontaneous meal size in rats. Physiol Behav, 2010,100:291-296.
[45] 林娟,周庆翰,赵晓军. 荧光光谱对自组装多肽作为药物载体的初步研究. 光谱学与光谱分析, 2009,29(10):2792-2797. Lin J, Zhou Q H, Zhao X J. Study on the designed self-assembling peptide as potential drug carrier by fluorescence spectra. Spectroscopy and Spectral Analysis, 2009,29(10):2792-2797.
[46] Alexander J,Dainiak N,Berger H J,et al. Serial assessment of doxorubicin cardiotoxicity with quantitative radionuclide angiocardiography. N Engl J Med, 1979,300:278-283.
[47] Von Hoff D D,Layard M W,Basa P,et al. Risk factors for doxorubicin-induced congestive heart failure. Ann Intern Med, 1979,91:710-717.
[48] Li Y,Zheng X,Cao Z,et al. Self-assembled peptide (CADY-1) improved the clinical application of doxorubicin. Int J Pharm, 2012,434:209-214.
[49] Veronese F M,Pasut G. PEGylation, successful approach to drug delivery. Drug Discov Today, 2005,10:1451-1458.
[50] Veronese F M,Schiavon O,Pasut G,et al. PEG-doxorubicin conjugates: influence of polymer structure on drug release, in vitro cytotoxicity, biodistribution, and antitumor activity. Bioconjug Chem, 2005,16:775-784.
[51] Chari R V. Targeted cancer therapy: conferring specificity to cytotoxic drugs. Acc Chem Res, 2008,41:98-107.
[52] Batrakova E V. Reversal of multidrug resistance by PEG-b-PLA polymeric micelles loaded with paclitaxel. Nanomedicine (Lond), 2011,6:1493-1494.
[53] Batrakova E V. Overcoming multidrug resistance using silica nanoparticles PEG-b-PLA polymeric micelles loaded with doxorubicin. Nanomedicine (Lond), 2011,6:1492-1493.
[54] Gou M,Shi H,Guo G,et al. Improving anticancer activity and reducing systemic toxicity of doxorubicin by self-assembled polymeric micelles. Nanotechnology, 2011,22:095102.
[55] Gou M,Zheng L,Peng X,et al. Poly(epsilon-caprolactone)-poly(ethylene glycol)-poly(epsilon-caprolactone) (PCL-PEG-PCL) nanoparticles for honokiol delivery in vitro. Int J Pharm, 2009,375:170-176.
[56] Gou M,Zheng X,Men K,et al. Poly(epsilon-caprolactone)/poly(ethylene glycol)/poly(epsilon-caprolactone) nanoparticles: preparation, characterization, and application in doxorubicin delivery. J Phys Chem B, 2009,113:12928-12933.
[57] Qu W,Chen W H,Kuang Y,et al. Avidin-biotin interaction mediated peptide assemblies as efficient gene delivery vectors for cancer therapy. Mol Pharm, 2013,10:261-269. |
|
Viewed |
|
|
|
Full text
|
|
|
|
|
Abstract
|
|
|
|
|
Cited |
|
|
|
|
| |
Shared |
|
|
|
|
| |
Discussed |
|
|
|
|
